ANTIANDROGEN MONOTHERAPY MARKET ANALYSIS

Antiandrogens are a class of drugs that prevent androgens such as testosterone and dihydrotestosterone (DHT) from mediating their biological effects in the body. Antiandrogens are used to treat men with prostate cancer, benign prostatic hyperplasia, pattern hair loss, hypersexuality, paraphilias, and priapism. In women and girls, antiandrogens are used to treat acne, seborrhea, hirsutism, and hyperandrogenism.

Antiandrogen monotherapy is an alternative treatment option to androgen-deprivation therapy (ADT) with surgical or pharmacological castration for metastatic prostate cancer. Surgical or pharmacological castration for metastatic prostate cancer are associated with loss of libido and impotence, and may not always be acceptable to the patient. Hence, antiandrogen monotherapy provides an alternative to castration in prostate cancer treatment, which is likely to boost growth of the antiandrogen monotherapy market over the forecast period.

Global Antiandrogen Monotherapy Market – Dynamics

The increasing approvals of new antiandrogen monotherapy drugs by regulatory authorities is expected to drive the market growth over the forecast period. For instance, in December 2019, Pfizer Inc. and Astellas Pharma Inc. received approval for a supplemental New Drug Application (sNDA) from the U.S. Food and Drug Administration (FDA) for XTANDI (enzalutamide), indicated for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).

Moreover, increasing prevalence of prostate cancer is likely to propel growth of the antiandrogen monotherapy market over the forecast period. According to the World Cancer Research Fund, prostate cancer is the second most common cancer diagnosed in males and fourth most common cancer occurring overall. The World Cancer Research Fund also estimated that around 1.3 million males were diagnosed with prostate cancer globally in 2018. Such high prevalence of prostate cancer is expected to increase demand for antiandrogen monotherapy in order to treat the disease.

Global Antiandrogen Monotherapy Market - Regional Insights

On the basis of region, the antiandrogen monotherapy market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. According to the American Society of Clinical Oncology (ASCO), around 191,930 new cases of prostate cancer is estimated to be diagnosed in the U.S., in 2020. North America holds a dominant position in the global antiandrogen monotherapy market due to increasing prevalence of prostate cancer in the region.

Europe is also showcasing high growth in antiandrogen monotherapy market due to increasing prevalence of prostate cancer. According to the Cancer Research UK, around 48,487 cases of prostate cancer were reported in the U.K. during 2015-2017.

Global Antiandrogen Monotherapy Market - Competitive Landscape

Key players operating in the global antiandrogen monotherapy  market include Pfizer Inc., Astellas Pharma Inc., F. Hoffmann-La Roche Ltd., AstraZeneca Plc, Abbott Laboratories, Takeda Pharmaceutical Company Limited, OSI Pharmaceuticals, Inc., Genentech Inc., Bristol-Myers Squibb Company, Novartis AG, Progenics Pharmaceuticals, Inc., ALZA Corporation, Sanofi SA, GlaxoSmithKline Plc, Amgen Inc, ANI Pharmaceuticals, Inc., and others.

Global Antiandrogen Monotherapy Market - Market Taxonomy

On the basis of type, the global antiandrogen monotherapy market is segmented into:

• Steroidal
  • Cyproterone Acetate
• Nonsteroidal
  • Bicalutamide
  • Flutamide

On the basis of disease indication, the global antiandrogen monotherapy market is segmented into:

• Prostate Cancer
• Benign Prostatic Hyperplasia
• Hirsutism
• Hyperandrogenism
• Others

On the basis of distribution channel, the global antiandrogen monotherapy market is segmented into:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

On the basis of region, the global antiandrogen monotherapy market is segmented into:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa